Connect with us

Business News

Nigeria is only African country barred from 2022 US visa lottery

Nigerian citizens have been declared not eligible to apply for US visa lottery for 2022.

Published

on

Nigerians have been barred from participating in the United States’ visa lottery in 2022.

This was disclosed in a document titled ‘Instructions for the 2022 diversity immigrant visa program (dv-2022)’ obtained from the US’ website on Thursday, October 15.

“In Africa, natives of Nigeria are not eligible for this year’s Diversity Visa program,” the document stated.

It stated that Nigeria was barred because more than 50,000 of its citizens immigrated to the United States in the previous five years.

Citizens of other African countries are eligible to apply, but “persons born in the areas administered prior to June 1967 by Israel, Jordan, Syria, and Egypt are chargeable,
respectively, to Israel, Jordan, Syria, and Egypt. Persons born in the Gaza Strip are chargeable to Egypt; persons born in the West Bank are chargeable to Jordan; persons born in the Golan Heights are chargeable to Syria.”

The document reads in part, “Applicants who are selected in the program (selectees) must meet simple but strict eligibility requirements to qualify for a diversity visa. The Department of State determines selectees through a randomized computer drawing. The Department of State distributes diversity visas among six geographic regions, and no single country may receive more than seven percent of the available DVs in any one year.

“For DV-2022, persons born in the following countries are not eligible to apply, because more than 50,000 natives of these countries immigrated to the United States in the previous five years: Bangladesh, Brazil, Canada, China (including Hong Kong SAR), Colombia, Dominican
Republic, El Salvador, Guatemala, Haiti, Honduras, India, Jamaica, Mexico, Nigeria, Pakistan, Philippines, South Korea, United Kingdom (except Northern Ireland) and its dependent territories, and Vietnam.

“Persons born in Macau SAR and Taiwan are eligible.”

Advertisement
Click to comment

Leave a Reply

Business

FG launches application for N75 billion Youth Investment Fund at 5% interest, how to apply

FG has flagged off the application for the N75 billion Nigeria Youth Investment Fund.

Published

on

The Federal Ministry of Youth and Sports Development, on Thursday, October 15, 2020, flagged off the application for the N75 billion Nigeria Youth Investment Fund (NYIF) recently approved by the Federal Government.

During the launch of the application, the Minister of Youth and Sports Development, Sunday Dare, said that the NYIF underscored the importance placed on youths by the current administration.

The Minister said that the fund, which is an initiative of the Federal Ministry of Youth and Sports Development and funded by the Central Bank of Nigeria (CBN), would be spread over 3 years to cater to youth-owned businesses and investment needs.

Sunday Dare stated, “I must mention the support we enjoyed from the Central Bank of Nigeria (CBN), which in line with the President’s directive, provided the initial N12.5 billion required for the Fund to operate in the remaining part of the year 2020.

“We are also grateful that the Ministry of Finance, Budget and National Planning has on its part, committed to providing the next tranche of the fund in the 2021 budget.’

The Minister said that the loan, provided under the NYIF, has an interest rate of 5% per annum and a tenor of 5 years with a moratorium of up to 12 months.

He explained that any youth who wished to apply as an individual or a non-registered business could draw up to N250,000, while youth-owned registered businesses could apply for up to N3 million.

Going further, he said, “Our commitment to seeing the youth succeed is such that the loan is bundled with training that will ensure business sustainability for successful applicants.

“It is my belief that the fund will grow to become a permanent feature of our society, where beneficiaries run successful businesses and repay the loans.”

The Minister said that application is available on the Nigeria Youth Investment Fund Application Portal on NIRSAL Microfinance Bank’s site, www.nmfb.com.ng; and the ministry’s website, www.youthandsport.gov.ngor www.noya.ng.

Applicants are expected to provide their Names, Email address, and Website (if available).

Continue Reading

Coronavirus

US Tennis player Sam Querrey accused of fleeing Russia on private jet after testing positive for COVID-19

Published

on

33 year old US tennis player Sam Querrey, has been accused of fleeing Russia on a private jet after he and his family tested positive for Covid-19.

Querrey and his wife had tested positive for the virus ahead of the St. Petersburg Open this week and were placed in quarantine at a  hotel, according to the tournament organizers.

Doctors had recommended Querrey and his family be moved to a private apartment but he did not allegedly answer the door when doctors were dispatched to evaluate his condition.

“Sam Querrey was scheduled to retest on Thursday, October 15, however, instead of acting in accordance with ATP rules and the tournament’s sanitary protocol, Sam Querrey was recorded leaving the hotel by hotel security cameras at 5.45 a.m. on October 13, with his family, without notifying the reception,”

“As Querrey told the ATP representative, he and his family left Russia on a private plane.” read a statement from organizers.

The ATP which is the World tennis controlling body, said it was aware of an incident “regarding a player’s serious breach of protocol”

Querrey has not won a grand slam singles title in his career but is ranked world number 47.

Querrey has not responded to the allegations as at press time.

Continue Reading

Coronavirus

WHO study reveals new discovery about remdesivir drug’s effect on Covid-19 patients

The study found that the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course.

Published

on

A World Health Organization (WHO) study has discovered that Gilead Sciences Inc’s remdesivir had little or no effect on COVID-19 patients’ length of stay in the hospital or chances of survival.

The only antiviral drug authorized for treatments of Covid-19 in the US failed to prevent deaths among patients.

The antiviral medication, among the first to be used as a treatment for COVID-19, was one of the drugs recently used to treat U.S. President Donald Trump’s coronavirus infection.

The results are from WHO’s Solidarity trial, which evaluated the effects of 4 potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries.

The study found that the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with COVID-19, the WHO said on Thursday.

The results of the trial, which were posted online on Thursday, October 15, 2020, are yet to be peer-reviewed or published in a scientific journal

Earlier this month, data from a U.S. study of remdesivir by Gilead showed that the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo in a trial comprising 1,062 patients.

Gilead told Reuters, “The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir.

“We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”

Remdesivir, which was originally developed as a treatment for Ebola and Hepatitis C, interferes with the reproduction of viruses by jamming itself into new viral genes.

WHO chief scientist Soumya Swaminathan said on Wednesday that during the study, hydroxychloroquine and lopinavir/ritonavir were stopped in June after they proved ineffective, but other trials continued in more than 500 hospitals and 30 countries.

Swaminathan said, “We’re looking at what’s next. We’re looking at monoclonal anti-bodies, we’re looking at immunomodulators and some of the newer anti-viral drugs that have been developed in the last few months.”

Remdesivir received emergency use authorization from the U.S. Food and Drug Administration on May 1, and has since been authorized for use in several countries.

Gilead, however, disputed the conclusions of the W.H.O. study on Thursday, noting that a variety of drugs and drug combinations had been evaluated under a wide range of circumstances and that more rigorous studies had found a benefit.

Continue Reading
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

Follow us on Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers

Trending